

89-92. (canceled)

93. A polynucleotide encoding the fusion protein of claim

1.

94-97. (canceled)

98. A pharmaceutical composition comprising: (a) the fusion protein of claim **1**, or a polynucleotide encoding the same; and (b) a pharmaceutically-acceptable excipient.

99. (canceled)

100. A method of treating cancer, the method comprising contacting a cell with the fusion protein of claim **1**, or a polynucleotide encoding the same.

101-111. (canceled)

112. The method of claim **100**, further comprising administering a fusion protein comprising IL-15 and IL-15R α .

113-118. (canceled)

119. The method of claim **100**, further comprising administering an effective amount of T cells engineered to express an exogenous receptor.

120-128. (canceled)

129. The method of claim **119**, wherein the engineered T-cells express a fusion protein comprising IL-15 and IL-15R α ; and/or a cell tag.

130. (canceled)

* * * * *